July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Colistin resistance in gram negative ocular infections: prevalence, clinical outcome and antibiotic susceptibility patterns
Author Affiliations & Notes
  • Sanchita Mitra
    Ocular Microbiology, L V Prasad Eye Institute, Bhubaneswar, India
  • Soumyava Basu
    L V Prasad Eye Institute, Bhubaneswar, India
  • Suryasnata Rath
    L V Prasad Eye Institute, Bhubaneswar, India
  • Srikant K Sahu
    L V Prasad Eye Institute, Bhubaneswar, India
  • Footnotes
    Commercial Relationships   Sanchita Mitra, None; Soumyava Basu, None; Suryasnata Rath, None; Srikant Sahu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 850. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sanchita Mitra, Soumyava Basu, Suryasnata Rath, Srikant K Sahu; Colistin resistance in gram negative ocular infections: prevalence, clinical outcome and antibiotic susceptibility patterns. Invest. Ophthalmol. Vis. Sci. 2019;60(9):850.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Colistin is considered the last line of defence against multi-drug resistant gram negative bacterial (GNB) infections. The purpose of this study was to determine prevalence, clinical outcome and susceptibility patterns to non-colistin antibiotics.

Methods : Clinical and microbiological data were collected from consecutive cases of GNB microbial keratitis, infectious endophthalmitis and orbital infections over 1 year. Isolates were identified by standard microbiological procedures, confirmed by Vitek 2 compact system and screened for colistin resistance by Broth Microdilution method. Other GNB panel antibiotics were tested by Kirby-Bauer disc diffusion method. Clinical outcome criteria are given in Table 1. Screening for plasmid mediated CLR was done by plasmid DNA extraction and PCR with mcr-1and mcr-2 probes. The primary aim was to determine prevalence of CLR in ocular GNB isolates in different ocular infections. Secondary aim was to correlate colistin resistance with clinical outcomes and to determine susceptibility of CLR isolates to non-colistin antibiotics.

Results : Of the 60 GNB isolates, 40% (n=24) were colistin resistant (~45% in keratitis and endophthalmitis, and 28% in others; Table 2). Poorer clinical outcome in the CLR group, was noted only in orbital infections (95% CI= 1.3- 20, RR=5.2, P=0.02), while in microbial keratitis and endophthalmitis groups, clinical outcomes were comparable between CLR and colistin sensitive (CLS) groups. Significantly higher resistance to amikacin, gentamycin and ceftazidime was seen in CLR isolates. No difference with CLS group was noted for other GNB panel antibiotics including quinolones and imipenem. Of the 16 isolates tested, plasmid mcr-1 mediated colistin resistance was seen in 1 isolate of Enterobacter cloacae while mcr-2 mediated resistance was seen in 3 isolates of Burkholderia cepacia and 1 isolate of Pseudomonas aeruginosa.

Conclusions : CLR, though widely prevalent in ophthalmic infections, probably has limited impact on clinical outcomes of these infections. Routine GNB antibiotics may not be effective in CLR infections. Finally, plasmid-mediated transfer may account for transmission of CLR in ocular infections.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Table 1: Clinical outcome criteria in 3 clinical groups
Table 2: Prevalence of colistin resistance (CLR) and distribution of isolates in each clinical group

Table 1: Clinical outcome criteria in 3 clinical groups
Table 2: Prevalence of colistin resistance (CLR) and distribution of isolates in each clinical group

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×